24th Global Immunology, Microbiology & Infectious Diseases Summit
  • Follow

Accepted Abstracts

The Induction of De Novo Autoimmune Biomarkers Production in Healthcare Professionals Vaccinated With BNT162b2

Maria Cristina Sacchi1*, Stefania Tamiazzo1, Marinella Bertolotti2, Daniela Ferrante3, Tatiana Bolgeo2, Carolina Pelazza2, Daniele Ielo4, Lisa Agatea5, Piera De Gaspari5, Maria Matilde Ciriello1 and Antonio Maconi2

1Autoimmunology and Analysis Laboratory Unit, SS Antonio and Biagio and C Arrigo Hospital, Alessandria, Italy
2IRFI (Infrastruttura Ricerca Formazione Innovazione), SS Antonio and Biagio and C Arrigo Hospital, Alessandria, Italy
3Dipartimento di Medicina Traslazionale, Universita degli Studi del Piemonte Orientale e SSD Epidemiologia dei Tumori, AOU Maggiore della Carita e CPO Piemonte, Novara, Italy
4Instrumentation Laboratory SpA, Werfen, Milan, Italy
5Laboratory department, Affiliated to Euroimmun, Padova, Italy

Citation: Sacchi MC, Tamiazzo S, Bertolotti M, Ferrante D, Bolgeo T et al (2021) The Induction of De Novo Autoimmune Biomarkers Production in Healthcare Professionals Vaccinated With BNT162b2. SciTech Immuno-Microbiology 2021.

Received: September 20, 2021         Accepted: September 22, 2021         Published: September 22, 2021


Introduction: The vaccine BNT162b2 was the first one to be approved and the first mRNA-based vaccine ever. Some vaccines are known to induce autoinflammatory mechanisms, most of those are mild and transient and only a minor part are pathogenic. To date, the literature has reported the existence of a link between autoimmunity and COVID-19. The aim of this study was to evaluate whether subjects vaccinated with BNT162b2, initially negative to autoimmune biomarkers, will show at 3 months after the second dose of vaccine, a de novo production of autoantibodies.
Methods: Blood samples of 155 healthcare professionals (HCPs) of our hospital (114 females and 41 males, age range 20-66 years, median age 46) vaccinated with COVID-19 mRNA BNT162b2 (Pfizer) were collected before (T0) and 3 months after the administration of the two doses of the vaccine (T1). All samples were analysed for the presence of a) antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA) (Indirect Immunofluorescence [IIF], Euroimmun); b) anti-myeloperoxidase (anti-MPO), anti-proteinase 3 (anti-PR3) and anti-citrullinated peptide antibodies (anti-CCP) ([FEIA], Thermo Fisher Scientific); c) anti-phospholipid antibodies (anticardiolipin [aCL], anti-beta-2- glycoprotein I [anti-ß-2GPI] (Chemiluminescence, Werfen). Clinical data were collected using the REDCap software (REDCap version 10.2.3©2020 Vanderbilt University).
Results: Fifty (32,3%) out of 155 HCPs, presented ANA and 15 (9,7%) ASMA at T0. In contrast at T1, 53/137 HCPs, were positive for ANA (38,7%) and 21 (15,3%) for ASMA at T1. Most importantly, 9 HCPs that were negative at T0 for ANA and 10 negatives for ASMA, display a newly generated positivity at T1. Nine HCPs had high positive levels of ß-2GPI IgG and aCL at all time points and the values did not significantly change after vaccination. 
Conclusions: our preliminary results regarding the BNT162b2 vaccine effects on the development of potential autoimmune events in healthy individuals revealed an induction of autoinflammatory mechanisms in a small percentage of HCPs, developing a de novo autoantibodies production after vaccination.
Keywords: Vaccine, Autoimmunity, Autoimmune biomarkers, Covid-19